Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp

Plain-language guide to PMID 19351731 (2009): double-blind randomized controlled trial study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-2.

Key Facts

PMID: 19351731
Journal: The Journal of clinical endocrinology and metabolism
Year: 2009
Study type: Randomized Controlled Trial
Authors: Veldhuis JD et al. (2 authors)
DOI: 10.1210/jc.2008-2767

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-2 in this randomized controlled trial publication.

Sex steroids are prominent regulators of pulsatile GH secretion.

An experimentally controlled sex-steroid milieu will permit detection of nonsteroidal factors that determine GH secretion.

Who Took Part

The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, men only.

Eleven young (age, 24 +/- 0.99 yr) and 11 older (64 +/- 2.4 yr) men participated in the study.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

What Was Measured

PubMed files the paper under topics including Diagnostic Techniques, Endocrine, Disorders of Sex Development, Gonadal Steroid Hormones, Gonadotropin-Releasing Hormone, Growth Hormone-Releasing Hormone, Leuprolide and Oligopeptides.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-2.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRP-2 compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

GHRP-2: A synthetic growth hormone secretagogue that activates the ghrelin receptor and can increase appetite.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.